May 24, 2006
Combining the alpha-blocker alfuzosin SR (Uroxatral) with the
phosphodiesterase type-5 inhibitor sildenafil citrate (Viagra)
appears to produce a greater therapeutic benefit in men with lower
urinary tract symptoms than either drug alone, researchers said
yesterday.
 |
May 24, 2006
Robert C. Flanigan, MD, was named the new secretary of AUA during
the association's business meeting yesterday. He is professor and
chair of urology at the Loyola University Health System, Maywood,
IL.
|
May 24, 2006
Intraprostatic injection of botulinum toxin type A (Botox) is a
safe and effective treatment in patients with symptomatic BPH that
results in improvements in symptoms and quality of life that may
persist for up to 1 year, researchers from Taiwan said.
|
May 24, 2006
Despite media images depicting middle-aged and older men embracing
the use of phosphodiesterase type-5 inhibitors to correct erectile
dysfunction, actual interest and usage in this population is
unknown.
|
May 24, 2006
Once-a-day tadalafil (Cialis) at dosages ranging from 5 mg to 20 mg
produces measurable benefits in men with BPH and lower urinary
tract symptoms, according to a multicenter study presented here
yesterday.
|
May 24, 2006
Cook Urological introduced on Tuesday a new biomaterial known as
Surgisis ES for the treatment of Peyronie's disease. Surgisis ES is
a natural biomaterial that provides a graft that is strong, easy to
handle, easy to use, and biocompatible, the company said. It
supports the growth of new fully vascularized host tissue in the
penis.
|
May 24, 2006
Two separate studies have found that men and women dealing with
infertility suffer from depression and anxiety at a greater rate
than the general population.
|
May 23, 2006
Long-term survival of inflatable penile prostheses (IPPs) that have
been in use over the past 2 decades is excellent, and the
reliability of those devices appears even more promising for the
enhanced models that have become more recently available, said
Steven K. Wilson, MD.
|
May 23, 2006
Stimulation of the pudendal nerve may be an alternative to sacral
neurostimulation (SNS) in the treatment of urinary voiding
dysfunction. Two studies presented yesterday indicate that pudendal
neurostimulation (PNS) is effective in patients who do not respond
to SNS.
|
| 
Brings you the latest news and information twice each month.
Urology Times archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.